GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 12.65
(0.4%)
CNY 12.65
(0.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 38.58 Million CNY | 110.57% |
| 2022 | -365.21 Million CNY | -6.1% |
| 2021 | -344.21 Million CNY | -37.66% |
| 2020 | -250.05 Million CNY | -4.36% |
| 2019 | -239.61 Million CNY | -82.31% |
| 2018 | -131.42 Million CNY | 27.17% |
| 2017 | -180.46 Million CNY | -1.8% |
| 2016 | -177.27 Million CNY | -848.94% |
| 2015 | -18.68 Million CNY | -142.55% |
| 2014 | 43.9 Million CNY | 2030.12% |
| 2013 | 2.06 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -5.3 Million CNY | -104.93% |
| 2024 Q2 | 100.91 Million CNY | 545.12% |
| 2024 Q1 | 15.64 Million CNY | -59.46% |
| 2023 Q3 | -340.56 Million CNY | -21.31% |
| 2023 Q2 | -280.74 Million CNY | -12.46% |
| 2023 Q1 | -249.63 Million CNY | 31.65% |
| 2023 FY | 38.58 Million CNY | 110.57% |
| 2023 Q4 | 38.58 Million CNY | 111.33% |
| 2022 FY | -365.21 Million CNY | -6.1% |
| 2022 Q4 | -365.21 Million CNY | -24.24% |
| 2022 Q3 | -293.95 Million CNY | -19.09% |
| 2022 Q2 | -246.83 Million CNY | 3.15% |
| 2022 Q1 | -254.85 Million CNY | 25.96% |
| 2021 Q2 | -400.65 Million CNY | -23.78% |
| 2021 Q1 | -323.68 Million CNY | -29.45% |
| 2021 FY | -344.21 Million CNY | -37.66% |
| 2021 Q3 | -323.62 Million CNY | 19.23% |
| 2021 Q4 | -344.21 Million CNY | -6.36% |
| 2020 Q4 | -250.05 Million CNY | 4.38% |
| 2020 Q1 | -230.89 Million CNY | 3.64% |
| 2020 FY | -250.05 Million CNY | -4.36% |
| 2020 Q2 | -519.91 Million CNY | -125.18% |
| 2020 Q3 | -261.49 Million CNY | 49.7% |
| 2019 Q4 | -239.61 Million CNY | 0.0% |
| 2019 Q2 | -163.13 Million CNY | -224.12% |
| 2019 FY | -239.61 Million CNY | -82.31% |
| 2019 Q1 | 131.42 Million CNY | 200.0% |
| 2018 Q2 | -77.12 Million CNY | -84.07% |
| 2018 Q4 | -131.42 Million CNY | 0.0% |
| 2018 FY | -131.42 Million CNY | 27.17% |
| 2018 Q1 | -41.89 Million CNY | 76.78% |
| 2017 FY | -180.46 Million CNY | -1.8% |
| 2017 Q4 | -180.46 Million CNY | 0.0% |
| 2017 Q1 | 177.27 Million CNY | 200.0% |
| 2017 Q3 | -180.46 Million CNY | 0.0% |
| 2016 Q1 | -233.13 Million CNY | -1147.94% |
| 2016 Q3 | -177.27 Million CNY | 23.96% |
| 2016 FY | -177.27 Million CNY | -848.94% |
| 2016 Q2 | -233.13 Million CNY | 0.0% |
| 2016 Q4 | -177.27 Million CNY | 0.0% |
| 2015 Q2 | -25.45 Million CNY | -24.44% |
| 2015 Q4 | -18.68 Million CNY | 0.0% |
| 2015 Q3 | -18.68 Million CNY | 26.61% |
| 2015 FY | -18.68 Million CNY | -142.55% |
| 2015 Q1 | -20.45 Million CNY | -146.58% |
| 2014 Q3 | 43.9 Million CNY | 0.0% |
| 2014 Q1 | 28.93 Million CNY | 0.0% |
| 2014 Q4 | 43.9 Million CNY | 0.0% |
| 2014 FY | 43.9 Million CNY | 2030.12% |
| 2013 FY | 2.06 Million CNY | 0.0% |